Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19013
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMalamou-Mitsi, V.en
dc.contributor.authorCrikoni, O.en
dc.contributor.authorTimotheadou, E.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorVrettou, E.en
dc.contributor.authorAgnantis, N.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T18:56:16Z-
dc.date.available2015-11-24T18:56:16Z-
dc.identifier.issn0250-7005-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19013-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration & dosageen
dc.subjectCarboplatin/administration & dosageen
dc.subjectCisplatin/administration & dosageen
dc.subjectDisease Progressionen
dc.subjectDrug Administration Scheduleen
dc.subjectEpithelial Cells/pathologyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectOvarian Neoplasms/*drug therapy/*metabolism/pathologyen
dc.subjectPaclitaxel/administration & dosageen
dc.subjectProportional Hazards Modelsen
dc.subjectProto-Oncogene Proteins c-bcl-2/*biosynthesisen
dc.subjectReceptor, erbB-2/*biosynthesisen
dc.subjectTumor Suppressor Protein p53/*biosynthesisen
dc.titlePrognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian canceren
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/17465257-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2007-
heal.abstractBACKGROUND: Several oncogenes and onco-suppressor genes have been implicated in epithelial ovarian carcinogenesis, but their clinical significance is not clear and conflicting data have been found in various studies. PATIENTS AND METHODS: The immunohistochemical expression of HER-2, p53 and Bcl-2 proteins was investigated in a cohort of 95 patients with advanced epithelial ovarian cancer (stages IIc-IV). These patients participated in a phase III randomized clinical trial and were treated either with paclitaxel/carboplatin, orpaclitaxel/carboplatin alternating with paclitaxel/cisplatin. RESULTS: Positive immunostaining for HER-2, p53 and Bcl-2 proteins was found in 18%, 70.5% and 69.5% of the cases, respectively. In multivariate analysis, older patients (< 63 vs. > or = 63 years, p < 0.001), worse grade (I-II vs. III, p = 0.04) and p53 expression (negative vs. positive, p = 0.002) were significant prognostic factors independently associated with survival. CONCLUSION: p53 status along with age and grade appear to be independent prognostic factors for survival in patients with epithelial ovarian cancer.en
heal.journalNameAnticancer Resen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Malamou-Mitsi-2007-prognostic significance of.pdf670.11 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons